Effect of endocrine changes on bone metabolism and bone mineral density in patients with polycystic ovary syndrome
HAN Zhe1 CUI Zhaohui1 LI Xinning1 LI Jiena2 ZHENG Zhixin3▲
1. Department of Orthopaedic Surgery, Heze Municipal Hospital, Shandong Province, Heze 274000, China;
2. Department of Obstetrics and Gynecology, Heze Municipal Hospital, Shandong Province, Heze 274000, China;
3. Department of Spine Surgery, Heze Municipal Hospital, Shandong Province, Heze 274000, China
Abstract：Objective To investigate the effect of endocrine hormonal changes on bone metabolism and bone mineral density in polycystic ovary syndrome (PCOS). Methods A total of 129 patients admitted to the Department of Gynecology and Obstetrics of Heze Municipal Hospital from January 2020 to September 2021 were selected as the research objects, 71 patients with PCOS were included in the PCOS group, and the remaining 58 premenopausal patients were included in the non PCOS group. The levels of serum 25-hydroxy vitamin D (25-[OH]VD), osteocalcin (OC), total N-terminal propeptide of typeⅠprocollagen (TP1NP), β-C-terminal telopeptide of type-Ⅰcollagen (β-CTX), total parathyroid hormone (PTH) and bone mineral density, related sex hormone were compared between two groups. Results The levels of luteinizing hormone/follicle stimulating hormone (LH/FSH), total testosterone (TT) and homeostasis model assessment-insulin resistance (HOMA-IR) in the PCOS group were higher than those of the non-PCOS group, the differences were statistically significant (P＜0.05). The levels of 25-(OH)VD, OC, β-CTX, TP1NP, total T value in the PCOS group were lower than those of the non-PCOS group, the differences were statistically significant (P<0.05). There were no significant differences in the levels of estradiol, PTH and plasma fasting insulin (FINS) between the two groups (P>0.05). Conclusion Endocrine changes in PCOS patients cause bone metabolism changes and bone mineral density decline, which provide important clinical data for preventing and delaying the occurrence of osteoporosis.
韩哲； 崔兆辉； 李新宁； 李婕娜； 郑智心. 多囊卵巢综合征患者内分泌变化对骨代谢及骨密度的影响[J]. 中国当代医药, 2022, 29(21): 75-77转81.
HAN Zhe； CUI Zhaohui； LI Xinning； LI Jiena； ZHENG Zhixin. Effect of endocrine changes on bone metabolism and bone mineral density in patients with polycystic ovary syndrome. 中国当代医药, 2022, 29(21): 75-77转81.
Di Bari F，Catalano A，Bellone F，et al.Vitamin D，Bone Meta-bolism，and Fracture Risk in Polycystic ovary Syndrome[J].Metabolites，2021，11（2）：116.
[2]
Krishnan A，Muthusami S.Hormonal alterations in PCOS and its influence on bone metabolism[J].J Endocrinol，2017，232（2）：99-113.
[3]
Vasikaran S，Cooper C，Eastell R，et al.International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis[J].Clin Chem Lab Med，2011，49（8）：1271-1274.
Li J，Chen X，Lu L，et al.The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis[J].Cytokine Growth Factor Rev，2020，52：88-98.
Bhattoa HP，Cavalier E，Eastell R，et al.Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood[J].Clin Chim Acta，2021，515：16-20.
Wei X，Zhang Y，Xiang X，et al.Exploring the Relationship of Bone Turnover Markers and Bone Mineral Density in Community-Dwelling Postmenopausal Women[J].Dis Markers，2021，2021：1-10.
[17]
Mu Y，Cheng D，Yin TL，et al.Vitamin D and Polycystic Ovary Syndrome：A Narrative Review[J].Reprod Sci，2021，28（8）：2110-2117.
京公网安备 11010502046607号